ArticleDiscover oncology2022

Pembrolizumab as a first line therapy in a patient with extensive mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case.

Raed Farhat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.